secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001140361-25-025835
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%
--------------------------------------------------------------------------------

- Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
- Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.
- Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.
- Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.
- FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/0001140361-25-025835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125025835/ef20051984_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-025835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer